Syndivia
Developer of cancer therapeutics designed to make new therapies for patients with difficult-to-treat tumor indications. The company offers targeted ADCs with optimal drug-to-antibody ratios, enabling ...
Valuation
$0
Share Price
N/A
Total Raised
$4.1M
Last Round
N/A